Altimmune to Participate at Two Upcoming Investor Conferences
May 07 2024 - 7:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that members of the Company’s management
team will participate and be available for 1x1 meetings at the
following investor conferences:
- JMP Life Sciences Conference (New York,
NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern
Time
- UBS Obesity Therapeutics Day (Virtual
Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m.
Eastern Time
The sessions will be webcast and can be accessed by visiting the
Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Richard
Eisenstadt Chief
Financial Officer
Phone:
240-654-1450 ir@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke
CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From May 2024 to Jun 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Jun 2023 to Jun 2024